Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5380738 A
Publication typeGrant
Application numberUS 08/065,730
Publication dateJan 10, 1995
Filing dateMay 21, 1993
Priority dateMay 21, 1993
Fee statusLapsed
Also published asCA2161769A1, DE69431056D1, DE69431056T2, EP0699192A1, EP0699192B1, US5719163, WO1994027980A1
Publication number065730, 08065730, US 5380738 A, US 5380738A, US-A-5380738, US5380738 A, US5380738A
InventorsBryan H. Norman, Len F. Lee, Jaime L. Masferrer, John J. Talley
Original AssigneeMonsanto Company
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US 5380738 A
Abstract
2-Substituted-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazoles or 2-substituted-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)oxazoles and derivatives thereof are found to posses significant antiinflammatory activity, especially useful for the treatment of arthritis without deleterious side effects.
Images(7)
Previous page
Next page
Claims(21)
What is claimed is:
1. A compound of the formula (I) ##STR3## wherein X and Y are independently fluoro or methylsulfonyl; and
R is
a) hydrogen;
b) alkyl of from one to ten carbon atoms optionally substituted by hydroxy;
c) alkenyl of from two to ten carbon atoms optionally substituted by hydroxy;
d) alkynyl of from two to ten carbon atoms optionally substituted by hydroxy;
e) cycloalkyl of from 3 to 7 carbons;
f) cycloalkylalkyl wherein cycloalkyl is as defined above and alkyl is of from one to three carbons;
g) aryl which is phenyl, thienyl or 1-, or 2-naphthyl wherein the aryl is optionally substituted by alkoxy of from one to four carbon atoms or halo;
h) aralkyl wherein ar is aryl as defined above and alkyl is of from one to three carbons;
i) diarylalkyl wherein aryl is as defined above and alkyl is of from one to four carbon atoms; or
j) QR1 wherein Q is alkylenyl of from one to four carbon atoms and R1 is COR2 wherein R2 is 1) OR3 wherein R3 is hydrogen or alkyl of from one to four carbon atoms or 2) NR4 R5 wherein R4 and R5 are independently hydrogen and alkyl of from one to four carbon atoms;
or a pharmaceutically-acceptable salt thereof;
provided one of X and Y is methylsulfonyl.
2. A compound of claim 1 wherein X is F and Y is SO2 CH3.
3. A compound of claim 1 wherein X is SO2 CH3 and Y is F.
4. A compound of claim 1 wherein R is phenyl.
5. A compound of claim 1 wherein R is 3-methoxybenzyl, diphenylmethyl or benzyl.
6. A compound of claim 3 which is 5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole, 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazolepropionic acid or its methyl ester.
7. A compound of claim 2 which is 4-(4-fluorophenyl)-2-(2-phenyl)ethyl-5-(4-(methylsulfonyl)phenyl)oxazole.
8. A compound of claim 2 which is 4-(4-Fluorophenyl)-2-methyl-5-methyl-5-[4-(methylsulfonyl)phenyl]oxazole.
9. A compound of claim 2 which is 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyl-oxazole.
10. A compound of claim 2 which is 2-Benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyloxazole.
11. A compound of claim 2 which is 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-(3-phenyl)propyloxazole.
12. A compound of claim 2 which is 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-propyloxazole.
13. A compound of claim 2 which is 2-(tertbutyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole.
14. A compound of claim 2 which is 4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-(methylsulfonyl)phenyl]oxazole.
15. A compound of claim 2 which is 4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-(methylsulfonyl)phenyl]oxazole.
16. A compound of claim 2 which is 2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole.
17. A compound of claim 2 which is 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole acetic acid or its ethyl ester.
18. A compound of claim 2 which is 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazolepropionic acid or its methyl ester.
19. A compound of claim 2 which is 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazolebutanoic acid or its methyl ester.
20. A pharmaceutical composition for the treatment of inflammation which comprises an antiinflammatory amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
21. A method of treating inflammation in a patient suffering therefrom which comprises administering a compound of claim 1 in unit dosage form.
Description
BACKGROUND OF THE INVENTION

The present invention relates to 4,5-oxazole derivatives and analogs thereof, pharmaceutical compositions containing them and methods of using them to treat inflammation and/or pain in mammals. More particularly, this invention relates to selected 2-substituted-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazoles or 2-substituted-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)oxazoles having antiinflammatory and/or analgesic activity without erosion of the stomach.

2,3-Diaryl-5-halo thiophenes are disclosed in U.S. Pat. No. 4,590,205 as analgesic or antiinflammatory agents. More particularly, 2,3-diaryl-5-bromo thiophenes are disclosed in U.S. Pat. No. 4,820,827 as having unexpected antiinflammatory and prostaglandin synthetase inhibitory activity for use in the treatment of inflammation and dysmenorrhea. Copending application U.S. Ser. No. 08/004,822 discloses 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiophene and its 2-substituted bromo analog among its preferred compounds for antiinflammatory activity.

WO/91/19708 discloses thiophenes having various 5-substituents, as well as, 2,3-substitutions having antiinflammatory activity.

U.S. Pat. No. 3,743,656 and U.S. Pat. No. 3,644,399, which is the parent of U.S. Pat. No. 3,743,656, disclose more generically both thiophene and furane derivatives having antiinflammatory activity.

Preparation of a wide-variety of asymmetric biaryl compounds including substituted thiophene, furane and pyrrol rings is disclosed in U.S. Pat. No. 4,990,647 having a suggested utility as precursors for brighteners, pharmaceuticals, plant protection active compounds and liquid crystal materials.

Pyrazole derivatives having antiinflammatory activity are disclosed in European Patent Application Number 90117983.8.

Agents for the treatment of hypertension are disclosed as alkyl-arylimidazole, thiazole and oxazole derivatives in U.S. Pat. No. 4,632,930.

More specifically, U.S. Pat. No. 3,578,671 discloses oxazoles substituted in the 2-position by a saturated or unsaturated aliphatic acid and having 4 and 5 substituents, including phenyl which may be further substituted. French 2156486 of Derwent Abstract No. 41925U-B and U.S. Pat. No. 4,051,250 both generically disclose compounds including 2-oxazolylmercaptoalkanoic acid (esters, amides or cyano derivatives) ring systems having 4,5-diaryl groups which are phenyls both unsubstituted or substituted by a wide variety of substituents and having antiphlogistic, analgesic and antipyretic activity, particularly useful for treating arthritis.

Diarylheterocycles are disclosed in CA114(5):42807w for use as drugs including use against rheumatic and arthritic diseases.

Other related disclosures include U.S. Pat. No. 4,001,228 for antiaggregating activity and U.S. Pat. No. 3,895,024 for intermediates in the production of antiinflammatory agents.

U.S. Pat. No. 4,489,084 describes oxazolyl (or thiazolyl) hydrazinoalkyl nitrile compounds having including two phenyl substituents which phenyls are also further substituted for use as antiinflammatory agents. U.S. Pat. No. 4,143,047 entitled "2-Sulfinyl and 2Sulfonyl Oxazoles" discloses such compounds as reactants to make 2-acylamino oxazole derivatives having antiallergic activity.

Additionally, German Patent No. 3030661 described in Derwent Abstract No. 26458 E/14 provides heteroarylpropargyl ethers as synergists in pesticides, EP 402-246A described in Derwent Abstract 90-370247/50 provides azolyl-substituted alkoxy-acrylate derivatives for use as fungicides and Japanese Patent No. 3014-562 A described in Derwent Abstract No. 91-067958/10 provides alkylene diamine derivatives useful as glutamic acid blockers.

The above references, that disclose antiinflammatory activity, show continuing efforts to find a safe and effective antiinflammatory agent. The novel oxazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts.

The invention compounds are found to show usefulness in vivo as antiinflammatory agents, particularly as antiarthritic agents without ulcerogenic side effects.

SUMMARY OF THE INVENTION

This invention relates to novel compounds of the formula (I) ##STR1## and a pharmaceutically acceptable salt thereof; wherein

X and Y are independently fluoro or methylsulfonyl; and

R is 1) hydrogen;

2) alkyl of from one to ten carbon atoms optionally substituted by hydroxy;

3) alkenyl of from two to ten carbon atoms optionally substituted by hydroxy;

4) alkynyl of from two to ten carbon atoms optionally substituted by hydroxy;

5) cycloalkyl of from 3 to 7 carbons;

6) cycloalkylalkyl wherein cycloalkyl is as defined above and alkyl is alkylenyl of from one to three carbons;

7) aryl which is phenyl, 2- or 3-thienyl or 1-, 2- or 3-naphthyl wherein the aryl is optionally substituted by alkoxy of from one to four carbon atoms or halo;

8) aralkyl wherein ar is aryl as defined above and alkyl is alkylenyl is of from one to three carbons;

9) diarylalkyl wherein aryl is as defined above and alkyl is alkylenyl of from one to four carbon atoms;

10) QR1 wherein Q is alkylenyl of from one to four carbon atoms and R1 is COR2 wherein R2 is 1) OR3 wherein R3 is hydrogen or alkyl of from one to four carbon atoms or 2) NR4 R5 wherein R4 and R5 are independently hydrogen and alkyl of from one to four carbon atoms;

The present invention is also a pharmaceutical composition for the treatment of inflammation comprising an antiinflammatory amount of a compound of the formula I together with a pharmaceutically acceptable carrier.

The present invention is also a method of treating a human suffering from an inflammatory disease which comprises administering a compound of the formula of I in unit dosage form.

DETAILED DESCRIPTION

"Lower alkyl of from one to four" or "ten carbons" in the present invention means methyl, ethyl, propyl, butyl or further pentyl, hexyl, heptyl or the like and isomers thereof respectively.

"Halogen is chloro, fluoro or bromo.

"Lower alkenyl of from two to ten carbons" means ethenyl, 1- or 2-propenyl, 1-, 2- or 3-butenyl and the like and isomers thereof.

"Lower alkynyl of from two to ten carbons" means ethynyl, 1- or 1-propynyl, 1-, 2- or 3-butynyl and the like and isomers thereof.

"Alkylenyl of from one to three" or "to four" is a bridging alkyl chain, i.e. having two open bonds, such as methylenyl, ethylenyl, propylenyl or further butylenyl and isomers thereof.

The compounds of the present invention may contain asymmetric carbon atoms, and, therefore, the instant invention may also include the individual diastereomers and enantiomers, which may be prepared or isolated by methods known to those skilled in the art.

In other words, any resulting racemate can be resolved into the optical antipodes by known methods, for example, by separation of the diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base. Racemic compounds of the present invention can thus be resolved into their optical antipodes e.g., by fractional crystallization of d- or 1-(tartrates, mandelates, or camphorsulfonate) salts.

Additional methods for resolving optical isomers, known to those skilled in the art may be used, for example, those discussed by J. Jaques, A. Collet, and S. Wilen in Enantiomers, Racemates, and Resolutions, John Wiley and Sons, New York (1981).

The compounds I of the invention may preferably be pharmaceutically acceptable salts. Such salts may be basic or acid salts, for example, sodium, potassium, ammonium, calcium, magnesium, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorate, camphorsulphonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate, or phosphate, sulfate, chloride, carbonate and the like. The compounds of the invention are acids, acid derivatives, or when possible basic amines. The basic amines may be used to make acid addition salts of pharmaceutically acceptable weak inorganic or organic acids. These may include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

The acid addition salts of said basic compounds are prepared either by dissolving the free base or acid of compound I in aqueous or aqueous alcohol solution or other suitable solvents containing the appropriate acid or base and isolating the salt by evaporating the solution, or by reacting the free base of compound I with an acid as well as reacting compound I having an acid group thereon with a base such that the reactions are in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of the present invention also are meant to include, where possible, hydrated species.

The preferred compounds of the present invention are the compounds of Formula I wherein R is n-propyl, 3-methoxybenzyl, phenyl or diphenylmethyl.

The more preferred compound is of the Formula I wherein R is phenyl.

General Procedure for the preparation of 4,5-(4-fluorophenyl)[(4-methylsulfonyl)phenyl]oxazole and Derivatives of the Formula I

The procedures utilized in the preparation of the compounds of the formula I of the present invention are essentially that shown by the following Schemes 1 and 2. ##STR2## TBDMSCl is tert-butyl-dimethylsilyl chloride MCPBA is meta-chlorperoxybenzoic acid.

Generally, the above process is carried out as follows:

The synthesis of oxazoles of general formula I (schemes 1 and 2) begins with either 1-(4-fluorophenyl)- 2-[4-(methylthio)phenyl]ethanone or 2-(4-fluorophenyl)1-[4-methylthio)phenyl]ethanone previously described in U.S. Pat. No. 3,647,858. Preparation of the silyl enol ether of this material is followed by oxidation with m-chloroperbenzoic acid to give the appropriate silylated benzoin. Desilylation of this material is achieved using aqueous trifluoroacetic acid to give the desired benzoin. Reaction of the benzoin with the appropriate acid chloride in the presence of pyridine gives the benzoin esters which may be converted to the oxazole upon treatment with ammonium acetate in refluxing acetic acid.

The following examples are not meant to limiting.

EXAMPLE 1 4-(4-FLUOROPHENYL)-2-HYDROXY-2-(2-PHENYL)ETHYL-5-(4-(METHYLSULFONYL)-PHENYL)OXAZOLE

Part 1

Preparation of 1-(4-Fluorophenyl)-2-Hydroxy-2-(Methylsulfonyl)Phenyl)Ethanone

A suspension of 2.03 g sodium hydride in 125 mL THF is stirred at 0° C. under a nitrogen atmosphere as a solution containing 20.0 g of 1-(4-fluorophenyl)-2-[4-(methylthio)phenyl]ethanone, as prepared in U.S. Pat. No. 3,647,858, in 100 mL of THF is added dropwise over 30 min. The reaction is allowed to warm to 25° C. for 18 h. The reaction is quenched by pouring into aqueous sodium bicarbonate. The mixture is extracted with ethyl acetate and the combined organic extracts dried over sodium sulfate. Concentration in vacuo provides a yellow oil, which solidified on standing to give 27.9 g of the silyl enol ether. NMR spectra is consistent with the assigned structure. The silyl enol ether is used without further purification.

A solution containing 27.9 g of the silyl enol ether in 500 mL CH2 Cl2 is cooled to 0° C. under a nitrogen atmosphere while being stirred mechanically. 77.1 g of m-chlorperoxybenzoic acid (technical grade, 50-60%) is added and the reaction is stirred at 0° C. for 2 h and allowed to warm to 25° C. over 1 h. The reaction mixture is washed with an aqueous solution of sodium metabisulfite, followed by aqueous sodium bicarbonate. The organic solution is dried over sodium sulfate and concentrated in vacuo to give 24.5 g of 1-(4-fluorophenyl)-2-tert-butyldimethylsilyloxy-2-[4-(methylsulfonyl)phenyl]ethanone. NMR spectra were consistent with the assigned structure. This material is used without further purification.

The benzoin silyl ether is dissolved in 100 mL of 90% aqueous trifluoroacetic acid and stirred at 25° C. for 18 h. The reaction is quenched by slowly pouring into saturated aqueous sodium bicarbonate solution. The product is extracted with ethyl acetate and the combined organic extracts are dried over sodium sulfate. Concentration in vacuo provided an oily solid, which is recrystallized from 50% ethyl acetate-isooctane to give 15.5 g of a crystalline white solid (mp 122-123° C.) whose structure is assigned as 1-(4-Fluorophenyl)-2-Hydroxy-2-(Methylsulfonyl)Phenyl)Ethanone on the basis of its spectral properties.

The isomeric benzoin, 2-(4-fluorophenyl)-2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethanone, is prepared analogously from 2-(4-fluorophenyl)-1-[4-(methylthio)phenylethanone.

Part 2

Preparation of 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole.

A solution containing 5.00 g of 1-(4-fluorophenyl)-2 -hydroxy-2-(4-(methylsulfonyl)phenyl)ethanone in 100 mL CH2 Cl2 is stirred at 25° C. as 6.60 mL of pyridine is added, followed by 3.61 mL of hydrocinnamoyl chloride.

The reaction is stirred at 25° C. for 48 h, after which the organic solution is washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo to give an oily solid. This material is recrystallized from 50% ethylacetate-isooctane to give 4.40 g of a beige crystalline solid (mp 152°-153.5° C.). NMR spectra are consistent with the assigned structure of 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-2-(2-phenyl)propionyloxy ethanone. This material is dissolved in 100 mL of glacial acetic acid and 7.70 g of ammonium acetate is added. The reaction is heated to reflux with stirring for 1.5 h, after which it is cooled to room temperature and poured into 100 mL of water. The product is extracted with ethyl acetate and the combined organic extracts washed with aqueous sodium bicarbonate, dried over sodium sulfate and concentrated in vacuo to give an oily solid which is recrystallized from 50% ethyl acetate--isooctane to give 3.55 g of a white crystalline solid (mp 117°-118° C.) which is 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole. NMR spectra is consistent with the assigned structure.

EXAMPLE 2

Using appropriate corresponding starting materials the following compounds are prepared in an analogous fashion:

Part 1) 4-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole, mp 158°-159° C.

Part 2) 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole, mp 204°-205° C.

Part 3) 2-Benzyl-4-(4-fluorophenyl) -5-(4-(methylsulfonyl)phenyloxazole, ms m/z 408 (M+H)+.

Part 4) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-(3-phenyl)propyloxazole, ms m/z.

Part 5) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-propyloxazole, ms m/z 436 (M+H)+.

Part 6) 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole, mp 130°-131 ° C.

Part 7) 4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-(methylsulfonyl)phenyl]oxazole, mp 123°-124° C.

Part 8) 4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-(methylsulfonyl)phenyl]oxazole, ms m/z.

Part 9) 2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole, mp 155°-156 ° C.

Part 10) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)-phenyl]oxazoleacetic acid, ethyl ester, mp 123°-124° C.

Part 11) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazolepropionic acid, methyl ester, ms m/z 404(M+H)+.

Part 12) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazolebutanoic acid, methyl ester, mp 89°-91° C.

Part 13) 5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole ms m/z 332 (M+H)+.

Part 14) 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazolepropionic acid, methyl ester ms m/z 404 (M+H)+.

The following acids were prepared from their corresponding esters via alkaline hydrolysis using 1N sodium hydroxide in methanol and appropriate reaction conditions.

Part 15) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-oxazoleacetic acid mp 118°-120° C.

Part 16) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-oxazolepropionic acid ms m/z 390 (M+H) +.

Part 17) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-oxazolebutanoic acid. ms m/z 404 (M+H)+.

Part 18) 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazolepropanoic acid ms m/z 390 (M+H)+.

Part 19) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl phenyl]-2-(3-hydroxy)propyloxazole is prepared by treating 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-oxazolepropanoic acid, methyl ester with diisobutylaluminum hydride. NMR spectra are consistent with the assigned structure, mp 123°-124° C.

Part 20) 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-oxazolepropionic amide is prepared by treating 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-oxazolepropionic acid, methyl ester with excess ammonia in methanol for 5 days, mp 193°-195° C.

Dosage Forms

The antiinflammatory agents of this invention can be administered to treat inflammation by any means that produces contact of the active agent with the agent's site of action in the body of a mammal, preferably human. These agents can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. The agents can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration, preferably oral, and standard pharmaceutical practice.

Total daily dose administered to the mammal, preferably human, in single or divided doses may be in amounts, for example, from 0.1 to 100 milligrams per kilogram of body weight. Ordinarily 0.5 to 50, and preferable 1 to 10 milligrams per kilogram per day given in divided doses 1 to 6 times a day or in sustained release form is effective to obtain desired results.

Dosage forms (compositions) suitable for internal administration contain from about 1 milligram to about 500 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The dosage regimen to give relief from or ameliorate a disease condition (i.e., treatment) having inflammation as an element of the disease, such as arthritis, or protecting against the further inflammation (i.e., prophylaxis) with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or setting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings, if necessary.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

Pharmaceutically acceptable carriers encompass all the foregoing and the like.

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents. For example, the compounds of the invention can be administered in combination with antihistamines or with other such agents known heretofore to be effective in combination with antiinflammatory agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be with in the scope and nature of the invention which are defined in the appended claims.

The examples herein can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

Adjuvant-Induced Arthritis in Rats

The antiinflammatory utility of the compounds of the present invention is shown by an assay essentially performed in an animal model using a procedure recognized to show antiinflammatory activity. See Winter et al in "Carrageenan-induced Edema in Hind Paw of the Rat" Proc. Soc. Exp. Biol. Med., 111, 544, 1962.

The IC50 shows the % decrease from control paw volume determined in this procedure and the data for a selected compound in this invention is summarized in Table 2.

              TABLE 2______________________________________       Rat Paw       ED40 mg/kg______________________________________Example 1Part 2        5______________________________________
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3578671 *Nov 6, 1967May 11, 1971Wyeth John & Brother LtdOxazoles
US3644399 *May 1, 1969Feb 22, 1972Wyeth John & Brother LtdPyrrole lower alkanoic acids and derivatives
US3743656 *Sep 15, 1971Jul 3, 1973Wyeth John & Brother LtdThiophene and furan lower alkanoic acids and derivatives
US3895024 *Jun 24, 1974Jul 15, 1975Serna AgProcess for preparing 4,5-diphenyl-oxazol-2-one
US4001228 *Jul 23, 1975Jan 4, 1977Serono Laboratories, Inc.Platelet aggregation inhibitors
US4020082 *Aug 5, 1975Apr 26, 1977Enzo MarchettiAntiphlogistic, analgesic, antiaggregant, local anesthetic
US4051250 *Oct 21, 1975Sep 27, 1977Merck Patent Gesellschaft Mit Beschrankter HaftungAntiinflammatory azole derivatives
US4143047 *Sep 26, 1977Mar 6, 1979Lilly Industries Limited2-acylamino oxazole intermediates which are antiallergens
US4489084 *Jun 30, 1983Dec 18, 1984Abbott Laboratories[1-(2-Oxazolyl) or -(2-thiazolyl) hydrazino]alkyl nitriles
US4532253 *Jul 11, 1984Jul 30, 1985John Wyeth & Brother LimitedOxaprozin calcium salt pharmaceutical compositions
US4590205 *Jan 17, 1984May 20, 1986E. I. Du Pont De Nemours And CompanyAntiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
US4632930 *Nov 30, 1984Dec 30, 1986E. I. Du Pont De Nemours And CompanyAntihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US4774253 *Oct 10, 1986Sep 27, 1988Hoffmann-La Roche Inc.Oxazole and isoxazole derivatives having anti-arthritic activity
US4775687 *Jun 2, 1986Oct 4, 1988Takeda Chemical Industries, Ltd.Thiazolidine derivatives, their production and use
US4791124 *Apr 2, 1987Dec 13, 1988Fmc CorporationPhotoactive azole pesticides
US4990647 *Apr 24, 1989Feb 5, 1991Bayer AktiengesellschaftCatalytic coupling of two different halogenaromatics
US5061705 *Feb 8, 1990Oct 29, 1991Basf AktiengesellschaftSkin disorders
US5206255 *Sep 26, 1990Apr 27, 1993Mitsubishi Kasei CorporationHeterocyclic compound
US5262540 *May 10, 1993Nov 16, 1993Bristol-Myers Squibb Company[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
EP0418845A1 *Sep 19, 1990Mar 27, 1991Fujisawa Pharmaceutical Co., Ltd.Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
EP0517591A1 *Jun 4, 1992Dec 9, 1992Laboratoire Roger BellonOxazole derivatives and their preparation
Non-Patent Citations
Reference
1 *Aldous et al., J. Org. Chem. vol. 25, pp. 1151 1154 (1960).
2Aldous et al., J. Org. Chem. vol. 25, pp. 1151-1154 (1960).
3 *Derwent Abstract 90 370247/50 (1990).
4Derwent Abstract 90-370247/50 (1990).
5 *Derwent Abstract No. 26458 E/14 (1982).
6 *Derwent Abstract No. 41925U B (1973).
7Derwent Abstract No. 41925U-B (1973).
8 *Derwent Abstract No. 91 067958/10 (1991).
9Derwent Abstract No. 91-067958/10 (1991).
10 *E.P. 418845 Sep. 19, 1990 Pyrazole derivatives, processes for preparation thereof & pharmaceutical composition comprising the same.
11Masferrer, et al. in Proc. Natl. Acad. Sci. USA, vol. 89, pp. 39173921 (May 1992) entitled "Endogenous glucocorticoids regulate an inducible cyclooxygenae enzyme".
12 *Masferrer, et al. in Proc. Natl. Acad. Sci. USA, vol. 89, pp. 39173921 (May 1992) entitled Endogenous glucocorticoids regulate an inducible cyclooxygenae enzyme .
13 *Meanwell et al. I Jour. Med. Chem. vol. 35 pp. 3483 3497 (1992).
14Meanwell et al. I Jour. Med. Chem. vol. 35 pp. 3483-3497 (1992).
15 *Meanwell et al. II Jour. Med. Chem. vol. 35 pp. 3498 3512 (1992).
16Meanwell et al. II Jour. Med. Chem. vol. 35 pp. 3498-3512 (1992).
17 *Raz, A., et al., Proc. Natl. Acad. Sci. USA 86, 1657 1661, 1989.
18Raz, A., et al., Proc. Natl. Acad. Sci. USA 86, 1657-1661, 1989.
19 *T. Hla and K. Neilson Proc. Natl. Acad. Sci. USA, vol. 89, pp. 7384 7388, (Aug. 1992) entitled Human cyclooxygenase 2 cDNA .
20T. Hla and K. Neilson Proc. Natl. Acad. Sci. USA, vol. 89, pp. 7384-7388, (Aug. 1992) entitled "Human cyclooxygenase-2 cDNA".
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5643933 *Jun 2, 1995Jul 1, 1997G. D. Searle & Co.Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5700816 *Jun 12, 1995Dec 23, 1997Isakson; Peter C.Antiarthritic agents
US5719163 *May 19, 1994Feb 17, 1998G.D. Searle & Co.Arthritis
US5750726 *Jun 27, 1997May 12, 1998American Cyanamid CompanyInsecticides; reaction of amide nitrile compound
US5777132 *Jun 27, 1997Jul 7, 1998American Cyanamid CompanyProcess for the manufacture of 2-aryl-5 perfluoroalkylpyrrole derivatives
US5866596 *Mar 24, 1997Feb 2, 1999Laboratories UpsaDrugs with antiinflammatory and analgesic properties.
US5925773 *Jun 27, 1997Jul 20, 1999American Cyanamid CompanyChemical condensation of olefin with oxazole derivative to form pyrrole
US5932598 *Jan 12, 1998Aug 3, 1999G. D. Searle & Co.Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US5945538 *Jun 27, 1997Aug 31, 1999American Cyanamid CompanyAmmonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
US5990148 *Jun 11, 1996Nov 23, 1999G.D. Searle & Co.Side effect reductions; antiarthritic agents; nonsteroidal antiinflammatory agents
US5994381 *Dec 18, 1995Nov 30, 1999Japan Tobacco, Inc.Antipyretics; antiinflammatory agents; analgesics
US6025353 *Nov 19, 1997Feb 15, 2000G.D. Searle & Co.Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6090834 *Dec 1, 1998Jul 18, 2000G.D. Searle & Co.Substituted oxazoles for the treatment of inflammation
US6136839 *Jun 11, 1996Oct 24, 2000G. D. Searle & Co.Using a sulfone or sulfoamide benzene compound
US6172096May 11, 1998Jan 9, 2001G. D. Searle & Co.Administering 4-pyrazolylbenzenesulfonamide derivatives to treat autoimmune diseases
US6333414 *Oct 26, 2000Dec 25, 2001L'ORéAL S.A.By reaction of thiourea with the corresponding diketone ester; carried out under reaction conditions, particularly with respect to ph, which are industrially more favorable.
US6342510Jun 11, 1996Jan 29, 2002G. D. Searle & Co.Antiinflammatory agents and enzyme inhibitors
US6362209Sep 17, 1999Mar 26, 2002Japan Tobacco Inc.Heterocyclic aromatic oxazole compounds and use thereof
US6376528Oct 18, 1999Apr 23, 2002G. D. Searle & Co.Synergistic mixture
US6407140Jan 21, 2000Jun 18, 2002G.D. Searle & Co.Autoimmune diseases, graft versus host disease and organ transplant surgery; pyrazole derivative mixture
US6432999Jun 11, 2001Aug 13, 2002Pharmacia CorporationPyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6436967Sep 14, 2000Aug 20, 2002Pharmacia CorporationProcess for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
US6512121Jun 11, 2001Jan 28, 2003G.D. Searle & Co.Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014Jun 11, 2001Feb 4, 2003G. D. Searle & Co.Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6613790Apr 16, 2002Sep 2, 2003Pharmacia CorporationProdrugs of COX-2 inhibitors
US6617345Sep 12, 2000Sep 9, 2003G.D. Searle & Co.Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides
US6649645Aug 27, 1999Nov 18, 2003Pharmacia CorporationCombination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6673818Apr 16, 2002Jan 6, 2004Pharmacia CorporationFluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
US6696477Nov 29, 2001Feb 24, 2004Pharmacia CorporationHeterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6699884Dec 13, 2002Mar 2, 2004Pharmacia CorporationAntiinflammatory cyclooxygenase inhibitors.
US6716829Jul 26, 2001Apr 6, 2004Pharmacia CorporationAldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US6753344Dec 12, 2002Jun 22, 2004Pharmacia CorporationThiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6815460Jun 24, 2002Nov 9, 2004Pharmacia CorporationProcess for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
US6846818Apr 16, 2003Jan 25, 2005Pfizer Inc.Selective inhibitors of cyclooxygenase-2
US6869968Sep 21, 1998Mar 22, 2005Allmirall Prodesfarma S.A.Such as 3-(4-fluorophenyl)-4-(4-methysulphonylphenyl)-2-(3H)-oxazolone; for treating colorectal cancer, fevers, and inflammation
US6875785 *Sep 25, 2002Apr 5, 2005Pharmacia CorporationNonsteroidal antiinflammatory agents, e.g., N-hydroxy-1-(4-sulfonyl or aminosulfonyl)phenyl)-(ring- substituted hetero-cyclyl)alkanamide or -urea; dual enzyme inhibitors with minimal side effects; asthma; antiallergens; antipyretics
US6887893Dec 16, 1998May 3, 2005Sankyo Company, LimitedMethods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6998415Jan 12, 2004Feb 14, 2006Pharmacia CorporationSubstituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US7067159Dec 5, 2003Jun 27, 2006New Chapter, Inc.administering supercritical plant extracts of rosemary, turmeric, oregano and ginger for prophylaxis of neoplastic growth
US7070816Dec 5, 2003Jul 4, 2006New Chapter, Inc.Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US7141599Jul 10, 2003Nov 28, 2006Pharmacia CorporationImmunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin
US7172769Dec 6, 2000Feb 6, 2007Pharmacia CorporationMethylsulfonylphenyl or phenylsulfonamide derivatives having ring selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine; celecoxib and rofecoxib; administered for pain; oral drug delivery
US7329401Jan 10, 2003Feb 12, 2008The Regents Of The University Of CaliforniaCyclooxygenase-2 selective agents useful as imaging probes and related methods
US7420061Sep 13, 2004Sep 2, 2008Pharmacia CorporationProcess for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US7449462Jan 11, 2005Nov 11, 2008Pfizer, Inc.2-{4-[4-(2-Ethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine; more potent, longer duration of action, broader range of activity, more stable, fewer side effects, selectivity; anxiety, cardiovascular disease, dysmenorrhoea, endometriosis, emesis, inflammation, sexual disorders
US7482367Aug 30, 2006Jan 27, 2009Novartis Vaccines And Diagnostics, Inc.Substituted benzimidazoles and methods of their use
US7553854Apr 18, 2007Jun 30, 2009Novartis Vaccines And Diagnostics, Inc.6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US7622142Sep 14, 2005Nov 24, 2009New Chapter Inc.Methods for treating glioblastoma with herbal compositions
US7695736Apr 1, 2002Apr 13, 2010Pfizer Inc.Powder of 30-90% a water-soluble cycloxygenase inhibitor, 5-60% of a buffer and 0-10% of other excipients
US7732465Dec 5, 2008Jun 8, 2010Novartis Vaccines And Diagnostics, Inc.{1-Methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine; inhibitors of kinase/Raf kinase activity associated with tumorigenesis, serine/threonine kinase or receptor tyrosine kinase; cancer; tumors; inhibit MAPK signaling pathway
US7745481Aug 13, 2004Jun 29, 2010Daiichi Sankyo Company, LimitedMethods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
US7767820May 5, 2008Aug 3, 2010Novartis Vaccines And Diagnostics, Inc.such as {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine via reduction, desulfurization; for treating kinase mediated disorders
US7790738Jul 20, 2001Sep 7, 2010Lauras AsMethods of treating and preventing AIDS using of COX-2 inhibitors
US7838023Nov 16, 2006Nov 23, 2010Nitromed, Inc.Ethanamine, 2-L[5-oxido-4-phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]-N,N-bis[2-[[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]ethyl]-; cardiovascular diseases; inhibiting platelet aggregation, platelet adhesion caused by the exposure of blood to a medical device; abnormal cell proliferation
US7879369Feb 18, 2008Feb 1, 2011Selvamedica, LlcCombretum laurifolium Mart. extract and methods of extracting and using such extract
US8067414Mar 19, 2007Nov 29, 2011Nicox S.A.Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8067464Oct 3, 2005Nov 29, 2011Nitromed, Inc.Compositions and methods using apocynin compounds and nitric oxide donors
US8173689May 8, 2009May 8, 2012Novartis Ag6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US8247423Jul 11, 2008Aug 21, 2012Tragara Pharmaceuticals, Inc.Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US8367038May 23, 2005Feb 5, 2013HMI Medical Innovations, LLCTherameutin modulators
US8431110Nov 24, 2006Apr 30, 2013Hmi Medical Innovations, Llc.Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US8541471Aug 4, 2009Sep 24, 2013Osteologix A/SWater-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US8592459Apr 13, 2010Nov 26, 2013Novartis AgSubstituted benzimidazoles and methods of their use
US8623422May 4, 2009Jan 7, 2014Osteologix A/SCombination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
US8680081Aug 27, 2001Mar 25, 2014Peter Van PattenProphylactic treatment of migraine
US8710048Apr 23, 2012Apr 29, 2014Novartis Ag6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
EP0995747A1 *May 31, 1996Apr 26, 2000G.D. SEARLE & CO.Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP1296971A2 *Apr 20, 2001Apr 2, 2003Pharmacia Corporation2-fluorobenzenesulfonyl compounds for the treatment of inflammation
EP1707199A1Mar 30, 2006Oct 4, 2006Astion Development A/SOxaprozin or closely related compound for the treatment and prevention of pruritus
EP1707200A1 *Mar 30, 2006Oct 4, 2006Astion Development A/SDermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases
EP1977749A1Oct 14, 1997Oct 8, 2008G.D. Searle LLCUse of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1996038442A1 *May 31, 1996Dec 5, 1996David L BrownSubstituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO2003049678A2Dec 2, 2002Jun 19, 2003Mark E FraleyMitotic kinesin inhibitors
WO2006007491A1Jun 27, 2005Jan 19, 2006Merck & Co IncMitotic kinesin inhibitors
WO2006102900A1 *Mar 30, 2006Oct 5, 2006Astion Dev AsDermatological compositions and salts for the treatment of dermatological diseases
WO2007016677A2Aug 2, 2006Feb 8, 2007Nitromed IncNitric oxide enhancing antimicrobial compounds, compositions and methods of use
WO2007087246A2Jan 22, 2007Aug 2, 2007Merck & Co IncJak2 tyrosine kinase inhibition
WO2009111354A2Feb 28, 2009Sep 11, 2009Tiger PharmatechTyrosine kinase inhibitors
Classifications
U.S. Classification514/304, 548/236, 548/235
International ClassificationA61P29/00, C07D413/12, A61P43/00, A61K31/425, A61K31/421, A61K31/42, A61K31/44, C07D263/10, C07D263/32, C07D263/14
Cooperative ClassificationC07D263/32, C07D413/12
European ClassificationC07D263/32, C07D413/12
Legal Events
DateCodeEventDescription
Mar 6, 2007FPExpired due to failure to pay maintenance fee
Effective date: 20070110
Jan 10, 2007LAPSLapse for failure to pay maintenance fees
Jul 26, 2006REMIMaintenance fee reminder mailed
Jul 30, 2002REMIMaintenance fee reminder mailed
Jul 9, 2002FPAYFee payment
Year of fee payment: 8
Jul 9, 1998FPAYFee payment
Year of fee payment: 4
May 21, 1993ASAssignment
Owner name: MONSANTO COMPANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NORMAN, BRYAN H.;LEE, LEN F.;MASFERRER, JAIME L.;AND OTHERS;REEL/FRAME:006591/0561
Effective date: 19930521